PT828513E - Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo - Google Patents

Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo

Info

Publication number
PT828513E
PT828513E PT95918111T PT95918111T PT828513E PT 828513 E PT828513 E PT 828513E PT 95918111 T PT95918111 T PT 95918111T PT 95918111 T PT95918111 T PT 95918111T PT 828513 E PT828513 E PT 828513E
Authority
PT
Portugal
Prior art keywords
parkinsonism
treatment
selective nmda
nmda antagonists
combinations containing
Prior art date
Application number
PT95918111T
Other languages
English (en)
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT828513E publication Critical patent/PT828513E/pt

Links

Classifications

    • GPHYSICS
    • G10MUSICAL INSTRUMENTS; ACOUSTICS
    • G10HELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00Instruments in which the tones are generated by means of electronic generators
    • G10H5/10Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Multimedia (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
PT95918111T 1995-05-26 1995-05-26 Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo PT828513E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (1)

Publication Number Publication Date
PT828513E true PT828513E (pt) 2004-05-31

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95918111T PT828513E (pt) 1995-05-26 1995-05-26 Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo

Country Status (26)

Country Link
US (1) US6258827B1 (pt)
EP (1) EP0828513B1 (pt)
JP (1) JPH11505828A (pt)
CN (1) CN1159325A (pt)
AT (1) ATE258067T1 (pt)
AU (1) AU696258B2 (pt)
BR (1) BR9602485A (pt)
CA (1) CA2219911C (pt)
CO (1) CO4700422A1 (pt)
CZ (1) CZ283979B6 (pt)
DE (1) DE69532482T2 (pt)
DK (1) DK0828513T3 (pt)
ES (1) ES2211904T3 (pt)
FI (1) FI974323A (pt)
HU (1) HUP9601419A3 (pt)
IL (1) IL118328A (pt)
MX (1) MX9709112A (pt)
NO (1) NO962130L (pt)
NZ (1) NZ286656A (pt)
PL (1) PL314413A1 (pt)
PT (1) PT828513E (pt)
RU (1) RU2176145C2 (pt)
SG (1) SG45479A1 (pt)
TR (1) TR199600436A2 (pt)
TW (1) TW470740B (pt)
WO (1) WO1996037226A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
CA2299400C (en) * 1997-10-24 2004-04-27 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
EP1235572A2 (en) 1999-10-29 2002-09-04 MERCK SHARP & DOHME LTD. Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US20040116436A1 (en) * 2002-10-08 2004-06-17 Tatton William G. Treatment of dementia and parkinson's disease
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
CA2537765A1 (en) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US7713990B2 (en) * 2005-01-13 2010-05-11 Neurosearch A/S 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
ES2627541T3 (es) * 2012-04-20 2017-07-28 Ucb Pharma, S.A. Métodos para tratar la enfermedad de Parkinson
BR112016021034A8 (pt) 2014-03-13 2021-06-29 Neuroderm Ltd composição farmacêutica, uso da mesma e kit
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5356905A (en) 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
JPH0788355B2 (ja) 1991-04-18 1995-09-27 フアイザー・インコーポレイテツド フェノール性2―ピペリジノ―1―アルカノールのプロドラグエステル
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
WO1996037226A2 (en) 1996-11-28
US6258827B1 (en) 2001-07-10
ES2211904T3 (es) 2004-07-16
IL118328A0 (en) 1996-09-12
HUP9601419A2 (en) 1997-09-29
BR9602485A (pt) 1998-04-22
HUP9601419A3 (en) 1998-01-28
DK0828513T3 (da) 2004-04-13
FI974323A0 (fi) 1997-11-25
CZ283979B6 (cs) 1998-07-15
FI974323A (fi) 1997-11-25
ATE258067T1 (de) 2004-02-15
HU9601419D0 (en) 1996-07-29
NZ286656A (en) 2001-03-30
CA2219911A1 (en) 1996-11-28
CN1159325A (zh) 1997-09-17
JPH11505828A (ja) 1999-05-25
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
CO4700422A1 (es) 1998-12-29
TR199600436A2 (tr) 1996-12-21
NO962130L (no) 1996-11-27
AU696258B2 (en) 1998-09-03
MX9709112A (es) 1998-02-28
CA2219911C (en) 2004-07-27
DE69532482T2 (de) 2004-11-25
TW470740B (en) 2002-01-01
WO1996037226A3 (en) 1996-12-27
NO962130D0 (no) 1996-05-24
PL314413A1 (en) 1996-12-09
CZ152496A3 (cs) 1998-04-15
AU5451996A (en) 1996-12-05
IL118328A (en) 2001-06-14
EP0828513B1 (en) 2004-01-21
EP0828513A2 (en) 1998-03-18
DE69532482D1 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
PT828513E (pt) Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60022050D1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
EP0900568A3 (en) AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
DE60045427D1 (de) Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
IL157413A0 (en) Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
MY118944A (en) Synergistic treatment for parkinsonism
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
EP0900567A3 (en) Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
Sahadevan et al. A comparative experimental study of the anticonvulsant effect of three calcium channel blockers in albino mice
Gowri Thilagam et al. Anti convulsant property of Melatonin in Electro and Chemo induced Convulsions in Rats.
BR9909791A (pt) Tratamento de distúrbios de ansiedade de modo geral com a partoxetina